Registration Dossier
Registration Dossier
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 202-608-3 | CAS number: 97-78-9
Carcinogenicity
Administrative data
Description of key information
Key value for chemical safety assessment
Carcinogenicity: via oral route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via inhalation route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Carcinogenicity: via dermal route
Endpoint conclusion
- Endpoint conclusion:
- no study available
Justification for classification or non-classification
Additional information
According to Regulation (EC) No. 1907/2006, Annex X, article 8.9.1, column 2, testing of carcinogenicity is not indicated, as several studies investigating the genetic toxicity of sarcosines and sarcosinates in-vitro have shown that the substances of this category are not genotoxic. Moreover, the chronic and subchronic repeated dose toxicity tests via the oral route conducted with Sodium N-lauroylsarcosinate (CAS 137-16-6) revealed no substance-related adverse effects indicative for carcinogenicity such as hyperplasia or pre-neoplastic changes (e. g. metaplasia).
Justification for selection of carcinogenicity via oral route endpoint:
No carcinogencity study is required, since the substance is not mutagenic, and no hyperplasia or pre-neoplastic lesions were observed in any of the available studies.
Justification for selection of carcinogenicity via inhalation route endpoint:
No carcinogencity study is required, since the substance is not mutagenic, and no hyperplasia or pre-neoplastic lesions were observed in any of the available studies.
Justification for selection of carcinogenicity via dermal route endpoint:
No carcinogencity study is required, since the substance is not mutagenic, and no hyperplasia or pre-neoplastic lesions were observed in any of the available studies.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.
